My ePortfolio Register   
 

Abstract | Full HTML Article | PDF ecancer 11 723 / https://doi.org/10.3332/ecancer.2017.723

Short Communication

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy

Ovarian cancer (OC) is the leading cause of death from gynaecological cancer. It is extremely hard to diagnose in the early stages and around 70% of patients present with advanced disease. Metronomic chemotherapy (MCT) is described as the chronic administration of, generally low, equally spaced, doses of chemotherapeutic drugs with therapeutic efficacy and low toxicity. This is an effective and low-cost way to treat several types of tumours, including ovarian cancer. Here, we present six cases of advanced ovarian cancer treated with MCT with low doses of cyclophosphamide, which showed clinical response and stable disease.

Keywords: ovarian cancer, metronomic chemotherapy, cyclophosphamide

Loading Article Metrics ... Please wait

Related articles

Case Report: Palliative hysterectomy for vaginal bleeding from breast cancer metastatic to the uterus

Abstract | Full Article | PDF Published: 14 Feb 2018 / https://doi.org/10.3332/ecancer.2018.811

Image Report: Radical en bloc peritonectomy in advanced ovarian cancer

Abstract | Full Article | PDF Published: 08 Feb 2018 / https://doi.org/10.3332/ecancer.2018.808

Review: Endometriosis and endometriosis-associated cancers: new insights into the molecular mechanisms of ovarian cancer development

Abstract | Full Article | PDF Published: 25 Jan 2018 / https://doi.org/10.3332/ecancer.2018.803

Review: Fertility preservation in gynaecologic cancers

Abstract | Full Article | PDF Published: 16 Jan 2018 / https://doi.org/10.3332/ecancer.2018.798

Conference Report: United against cancer: prevention to end-of-life care—highlights from the Uganda Cancer Institute–Palliative Care Association of Uganda Joint International Conference on Cancer and Palliative Care and the 7th Palliative Care Conference, 24–25 August 2017, Kampala, Uganda

Abstract | Full Article | PDF Published: 14 Dec 2017 / https://doi.org/10.3332/ecancer.2017.790



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence